BiotechTube

ISL/LEN + Antiretroviral Combinations

Phase 3Active
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HIV-1-Infection

Conditions

HIV-1-Infection

Trial Timeline

Oct 8, 2024 → Aug 1, 2030

NCT ID
NCT06630299

About ISL/LEN + Antiretroviral Combinations

ISL/LEN + Antiretroviral Combinations is a phase 3 stage product being developed by Merck for HIV-1-Infection. The current trial status is active. This product is registered under clinical trial identifier NCT06630299. Target conditions include HIV-1-Infection.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06630299Phase 3Active

Competing Products

20 competing products in HIV-1-Infection

See all competitors
ProductCompanyStageHype Score
CVC 150 mg + CVC 300 mgAbbViePhase 2
52
18F-RaltegravirMerckPhase 1
33
Delstrigo + KOCITAFMerckPhase 3
77
ISL/LEN + B/F/TAF + PTM B/F/TAF + PTM ISL/LENMerckPhase 3
77
B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboGilead SciencesApproved
84
GS-3242 + BVY + Standard of CareGilead SciencesPhase 1
32
B/F/TAFGilead SciencesApproved
84
Genvoya + Epclusa + BiktarvyGilead SciencesApproved
84
GS-1720 + GS-4182 + Bictegravir/emtricitabine/tenofovir alafenamide + GS-1720/GS-4182 FDC + Placebo to Match BVY + Placebo to Match GS1720/GS-4182 FDCGilead SciencesPhase 2/3
64
Dapivirine + TruvadaGilead SciencesPhase 2
51
Bictegravir/emtricitabine/tenofovir alafenamideGilead SciencesPre-clinical
22
GS-9131 + BIC + TAF + ARV regimen + DRV + RTVGilead SciencesPhase 2
51
Bavtavirine + B/F/TAF + Standard of Care (Substudy 01) + GS-1720 + Standard of Care (Substudy 02) + GS-6212 + Standard of Care (Substudy 03)Gilead SciencesPhase 1
32
TruvadaGilead SciencesPhase 2
51
B/F/TAFGilead SciencesPhase 1
32
Switch to B/F/TAF + Continue current regimenGilead SciencesApproved
84
B/F/TAF + F/TAF + DTG + DTG Placebo + F/TAF Placebo + B/F/TAF PlaceboGilead SciencesPhase 3
76
GS-1720 + GS-4182 + Placebo to Match BVY + Bictegravir/emtricitabine/tenofovir alafenamide + GS-1720/GS-4182 FDC + Placebo to Match GS1720/GS-4182 FDCGilead SciencesPhase 2/3
64
Vesatolimod + VRC07523LS + CAP256V2LSGilead SciencesPhase 2
51
F/TAF (High Dose Tablet) + F/TAF (Low Dose Tablet) + F/TAF (Lowest Dose Tablet) + F/TAF (High Dose TOS) + F/TAF (Low Dose TOS) + F/TAF (Lowest Dose TOS) + E/C/F/TAF + E/C/F/TAF (Low Dose) + Cobicistat (High Dose) + Cobicistat (Low Dose) + Cobicistat (TOS) + B/F/TAF (High Dose) + B/F/TAF (Low Dose) + B/F/TAF (High Dose TOS) + B/F/TAF (Low Dose TOS) + B/F/TAF (Lowest Dose TOS) + 3rd ARV Agent + Nucleos(t)ide reverse transcriptase inhibitors (NRTI) + ATV + DRV + Lopinavir Boosted with ritonavir (LPV/r)Gilead SciencesApproved
84

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85